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Protein aggregation trends in neurodegenerative diseases are largely unmapped
due to the complex nature of protein-protein interactions and their regulatory
machineries such as protein proteolytic systems. Since the protein aggregation
process in humans is a slow process, early determination of the patients that will
develop neurodegenerative diseases later in life is critical in terms of starting effec-
tive treatment, which will reduce the expensive health care. In this chapter, I will
discuss the nature of protein aggregation of signature proteins and the status of
protein proteolytic systems such as proteasome and autophagosome in Alzheimer’s
disease, Parkinson’s disease, amyotrophic lateral sclerosis, frontotemporal lobar
degeneration, Huntington’s disease, and prion disease under the light of recent
studies including our new findings.
Keywords: protein aggregation, protein misfolding, neurodegenerative disease,
aging, proteinopathy, amyloid plaque
1. Introduction
Extracellular deposits of protein aggregates are often relevant to human diseases
in general. Protein aggregates are the product of misfolded proteins that escape
from protein quality checkpoints such as the chaperon/chaperonin system, heat
shock proteins (Hs90, Hs70, etc.), proteasomes, and the autophagosome system.
They are mostly insoluble and tend to form amyloid plaques over time. In this
chapter, I will review trends of protein aggregation in the most studied neurode-
generative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis
(ALS), Parkinson’s disease (PD), frontotemporal lobar degeneration (FTLD), prion,
Huntington’s disease, etc.
1.1 An overview for protein-folding
Biological self-assembly of proteins in a compact three-dimensional (3D) struc-
ture is the universal example of how the functional proteins can be separated from
other biomolecules. This feature provides a functional advantage for proteins. 3D
folding brings functional groups to close proximity creating a space where chemical
reactions can occur; hence, the protein molecule becomes functional. Properly
folded proteins need to maintain their stability which requires naturally interacting
partners during their life term [1]. Failure of this native environment-protein
interaction can lead to a wide variety of pathological conditions called proteinopathy.
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Approximately 30 or more structurally different proteins have the potential to
form an amyloid structure. Although there is no obvious homology in their
primary structure, they all share a beta-pleated sheet (β-structure) as a polymer
scaffold [3].
1.2 Energy landscape in protein-folding
Proteins in their native state, under the physiological conditions, are in a low
energy state which provides thermodynamic stability [4]. With a large number of
permutations, a systematic search for a stable polypeptide chain requires an enor-
mous length of time (1.6 1015 trillion years). This makes it clear that the protein-
folding process does not involve sequential steps. Cyrus Levinthal’s calculation
known as Levinthal’s paradox reveals that proteins do not follow a folding process by
trying every possible conformation; instead, they follow a partially defined pathway
consisting of intermediates between fully denatured protein and its native structure
(Figure 1) [1]. Two basic questions have not yet been answered: (i) what deter-
mines the correct folding state from the intermediate stage and (ii) how is the
energy landscape unique to a specific protein-folding? Folding characteristics of
small proteins (100 amino acid residue) provide invaluable information about the
amino acid sequence and energy landscape. A specific mutation in an amino acid
sequence may provide critical information about the folding and unfolding kinetics
[5]. Therefore, the energy landscape of certain signature proteins in neurodegener-
ative diseases may provide some critical information about the trends of such pro-
teins that misfold and form aggregate. The problem lies on how to study the specific
energy landscape of such proteins that are obtained from the patients (AD, ALS,
PD, Creutzfeldt-Jakob disease, and Huntington’s disease), which will predict the
aggregate formation of the proteins. This will help in designing new drugs that
either postpone or eliminate such aggregate formations; consequently, treatment
options for neurodegenerative diseases may be possible.
Figure 1.
Components of a partially denatured protein solution. In a half-unfolded protein solution, half of the protein
species are fully folded and the other half are unfolded. This is an experimental condition; therefore, it is not
known whether same or similar condition is existing in biology. The image is redrawn from 6th Edition of
Biochemistry [1].
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1.3 Protein misfolding in the cell
Although protein-folding principles are universal, the protein-folding environ-
ment needs to be taken into consideration in order to comprehend the protein-
misfolding event. Some protein-folding is co-translational; they are initiated before
leaving the ribosomal machinery upon completion of primary structure [6]. Most
proteins undergo proper folding process in the cytoplasm after they leave the
ribosome “quality control checkpoints” and began to interact with chaperones and
heat shock proteins (HSPs). Recent studies reveal that molecular chaperones are
essential not only in preventing misfolding but also in rescuing misfolded proteins
even in their early stage of aggregation enabling them to have a “second chance” to
fold correctly; this process requires ATP [7, 8]. Increased concentration of chaper-
one molecules and HSPs during cellular stress supports the notion that ATP is
required [9]. Chaperonins, a subclass of chaperones, are the preferred molecules
participating in the protein-folding process [10–12]. A possible chaperonin-naïve
protein adverse interaction may very well initiate protein misfolding that will lead
to protein aggregation. There are other proteins that complete their folding process
in certain organelles such as the endoplasmic reticulum (ER) and mitochondria
after being translocated into these organelles [7, 8]. The ER contains a large reper-
toire of molecular chaperons and folding catalysts [13, 14], making this organelle a
major folding site and also the source of misfolded protein-related diseases [15].
Such organelles may utilize internal signals that allow certain proteins to penetrate
into cell organelles to complete their folding. Wang et al. [16] recently demon-
strated that a nuclear protein transactive response DNA-binding protein 43 kDa
(TDP-43) penetrates into mitochondria using such internal signals and binds, pref-
erably mitochondria-transcribed mRNA that encodes respiratory complex-I sub-
units (ND3 and ND6). This subsequently interferes with the proper assembly of
complex-I and mitochondrial functions causing them to be impaired. The mito-
chondrial Hsp60/Hsp10 chaperonin system is essential for proper folding of pro-
teins that are transported from cytosol to the inside of mitochondria via porins, and
any mutation on this mitochondrial chaperonin system could be associated with
neurodegenerative diseases [17].
Many misfolded proteins that escaped the “quality control checkpoints” have
exposed regions that are normally buried in the hydrophobic core of the protein.
Such regions could inappropriately interact with other macromolecules within the
crowded bioenvironment of the cytosol [18]. This leads to the initiation of protein
aggregation that may be the foundation of protein-relevant disease, proteinopathy.
The readers should have a broad perspective of diverse process like translocation
across the membranes, trafficking, secretion, the immune response, and regulation
of the cell cycle that are dependent on the protein-folding mechanism [19]. Any
failure of proper folding or the escape from quality control checkpoints gives rise to
cell malfunctioning and, hence, to development of a proteinopathy [20, 21]. Protein
propensity can determine the probability of misfolded protein that has a relatively
higher extracellular milieu. Such protein propensity can be analyzed by employing
Predictors of Naturally Disordered Regions (PONDR) analysis. A few representa-
tives of neurodegenerative disease hallmark proteins’ PONDR® analysis were
performed based on their primary amino acid sequence, and the results were shown
in Figure 2. All four proteins possess reasonably high levels of disorder region that
makes the protein a good candidate to undergo aggregation process once the neces-
sary environmental conditions are achieved.
Protein misfolding is likely to initiate the formation of the seed for aggregation.
Therefore, researchers have studied the protein-folding chaperone machinery and
HSPs in the context of neurodegenerative disease [22]. Mutant Cu/Zn superoxide
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dismutase (SOD1G93A) abundant in motor neurons and HSP interactions was
studied. The proposal was made and experimentally demonstrated that mutant
SOD1 binding to HSPs (Hsp70 and Hsp25) makes this chaperone unavailable for
their anti-apoptotic functions and eventually leads to motor neuron death [23]. Our
laboratory has also demonstrated both in vitro and in vivo that mutant SOD1 failed
to bind calcineurin (CaN) in a fashion that CaN lost its activity [24]. This failed
interaction may yield the accumulation of hyper-phosphorylated protein aggrega-
tions [25] since CaN is one of the Ser-/Thr-specific phosphatase that removes the
phosphate from proteins [26]. Under the light of existing literature, it is now known
that a number of diseases such as AD, PD, prion disease, and typ. 2 diabetes are
directly relevant to aberrant proteins that escaped from chaperone quality check
system and form insoluble aggregates [21, 27–29].
1.3.1 Amyloid formation
Filament-like (fibrous) protein aggregates are generally referred to as amyloid.
The word amyloid indicates a starch-like compound. It is an accepted term for a
group of conformational disorders. About 30 or so proteins have the tendency to
form amyloid structure, and they are involved in the well-defined amyloidosis
Figure 2.
Prediction analysis of some of the signature proteins for neurodegenerative diseases. PONDR® score predicts the
disorder probability for a given protein or polypeptide based on the amino acid sequence. Disordered regions are
defined as the entire proteins or regions of proteins that lack a fixed tertiary structure. These figures represent
disordered regions of major proteins in neurodegenerative diseases. The black rectangle on the 0.5 line indicates
the region that was visible in the crystal structure with this protein bound to its binding partner (www.
molecularkinetics.com; main@molecularkinetics.com) under license from the WSU Research Foundation.
PONDR® is copyright C_1999 by the WSU Research Foundation, all rights reserved).
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(amyloidosis: abnormal proteins called amyloids buildup in the tissue). Although
there is no consensus homology in their amino acid sequence and molecular details
of amyloid fibrils have some commonalities, among them are as follows: (i) all share
β-sheet as a polymer scaffold; (ii) all show specific optical behavior on binding dye
molecule Congo red, displaying long-unbranched and often twisted structures; and
(iii) a characteristic cross-beta X-ray fiber differentiation pattern [3, 30]. Sequence
characteristics of certain regions, especially at either N- or C-terminal, may predict
the protein propensity to form amyloid fibrils. PONDR® (Figure 2) analysis shows
known neurodegenerative disease protein’s tendency to form amyloid fibers. The
idea that the relative aggregate rates for a wide range of polypeptides and proteins
correlate with the physicochemical features of the molecules such as charge,
secondary structure propensities, and hydrophobicity [31] was experimentally
supported.
It is now known that polypeptides or proteins that have propensity for β-pleated
structure have a tendency to form amyloid plaques. These β-pleated-enriched pro-
teins fall to the lowest energy level in the energy landscape (Figure 3), and they are
more hydrophobic. Consider a globular protein; the main polypeptide chain and
hydrophobic regions are buried in the core of the protein. When these regions are
exposed to more hydrophilic environment due to partial unfolding caused by low
pH, proteolytic fragmentation, etc., conversion to amyloid fibrillation becomes
possible [9]. Amyloid fibril formation takes years before it reveals clinical manifes-
tation, and the fibril formation follows a lag phase followed by a period of rapid
growth [32, 33]. The fibril structure is measurable and determinable by laboratory
techniques; however, it requires postmortem tissues. It is now critical to develop
some approaches that utilize less invasively obtained biosamples (e.g., blood) so
that protein fibrillation may be monitored and fibril formation can be restrained
with at early stages as part of early treatment option.
Figure 3.
Energy landscape of protein folding and aggregation. The purple surface shows possibility of the conformations
leading to the thermodynamically balanced state (native state). Cyan-colored area of the landscape indicates
the conformations moving toward to amorphous aggregates of insoluble amyloid fibrils (adopted and redrawn,
Vabulas et al. [34].
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1.3.2 Proteolysis-generated toxic protein species
Thermodynamic stability of a protein and its conformational kinetic determines
the state of proper folding. Amyloid fibrils maintain the thermodynamically stable
conformation in a highly organized hydrogen-bonded structure that is insoluble in
aqueous media. This structure takes many years to progressively build up in tissues.
Cellular homeostasis recognizes this event as toxic event and begins to encapsulate
the amyloid fibrils in a plaque formation as part of the cellular defense mechanism.
This plaque formation slows down and can eliminate further growth of the subse-
quent conversion of additional quantities of the same protein into amyloid fibrils
[9]. However, readers should be aware that there are some naturally occurring
nonpathogenic amyloid-like fibril formations such as the nanostructure of certain
bacteria [35] and the mammalian melanocyte integral membrane protein [36]. The
pathogenesis of amyloidogenic proteinopathy may be initiated with amyloidogenic
peptide fragments by one or more proteases [37]. Human amyloid pathologies
known to require proteolytic processing of a precursor protein include AD where
Aβ peptide fragments are liberated from a large APP precursor protein by β- and γ-
secretases [38]. A new potential biomarker for AD TDP-43 [39] may be involved in
activating β-secretase that will generate Aβ peptide fragments [2]. Figure 4 illus-
trates a simplified diagram of APP processing [2]. Modulation of Aβ generation by
bio-metals was studied in both cell-free and cell-based assays. It was found that zinc
(Zn2+) ion induces APP-C99 dimerization, which prevents APP cleavage by γ-
secretase and Aβ production [40]. The same group reported that copper (Cu2+) ion
was a γ-secretase inhibitor affecting APP processing [40]. These findings may
suggest that the metal dyshomeostasis is a critical issue in generation of toxic
protein species.
1.3.3 Proteasome malfunctioning
The β-sheet structure-enriched amyloid fibril formation relevant to protein
aggregation is tightly controlled by molecular chaperones and the proteasome
machinery. The proteasome is a large multisubunit complex that can be analogous
to a food waste disposer. The proper function of such system is absolutely necessary
for maintaining cell homeostasis [41].
It is expected that any proteasomal abnormalities may contribute to misfolding
and protein aggregation diseases [42, 43]. In a pilot study, we observed that
proteasome activity levels were reduced in plasma/platelet obtained from AD and
ALS patients (Figure 5), while TDP-43 protein levels were increased in platelets
Figure 4.
Simplified diagram of APP structure and processing. APP undergoes sequential proteolysis by β-secretase, α-
secretase, and γ-secretase for the release of Aβ from the neuronal plasma membrane. TDP-43 has been shown
to increase intraneuronal Aβ accumulation via increased β-secretase activation (adapted and modified from
Ref. [2]).
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obtained from AD patients (Figure 6). This suggests that proteasome machinery
was either malfunctioning or overwhelmed due to massive protein aggregation.
Proteasome activity measurements in human plasma were successfully performed
as a useful potential marker for various malignant and nonmalignant diseases [44].
Amyloid fibril formation that leads to abnormal protein aggregation may result in
two functional consequences: (i) a toxic gain of function and (ii) a loss of function
of the protein in question. Although the mature and organized protein fibrils are
usually benign [32, 45], it is not well documented how disordered amyloid fibrils
are being converted to malfunctioned protein species. One thought would be that
the nonnative hydrophobic surfaces of the aberrant protein’s interaction with cell
membrane or other cellular components may initiate cell death [46].
Figure 5.
Proteasome activity measurements in plasma. Extracellular proteasome activity levels were measured by
proteasome 20S assay fluorogenic system (Enzo Biochem Inc. cat#BML-AK740-0001) designed to measure
chymotrypsin-like protease activity of purified 20S proteasome. The detection of proteolytic activity is based on
the release of three fluorogenic peptides. About 50% decrease in proteasome activity were observed in AD and
ALS patient plasma (n = 3) (unpublished data).
Figure 6.
Platelet lysate TDP-43 profile. TDP-43 protein levels were determined in platelet lysate by Western blotting
method with a TDP-43 Ab (1:1000 dilution). Blood samples were obtained from AD patients (n = 3) and age-
matched healthy subject (n = 3). Approximately <60% increase were observed in TDP-43 levels in AD patients
(the figure was reproduced by permission [39]).
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2. Trends for misfolded proteins lead to neurodegeneration
Insoluble extracellular protein deposits in various human diseases have been
recognized for a long time. Many proteins that have a tendency to be misfolded do
form aggregates that initiate cellular dysfunction [47]. This section discusses how
the proteins involved in neurodegenerative disease have a tendency to misfold. If
we comprehend the biochemical and biophysical behavior of the proteins and their
misfolding features, we will have a better understanding of proteinopathy and
relevance to neurodegenerative diseases.
2.1 Common protein behavior in aggregation
In the last 25 years or so, many diseases have been linked to protein-misfolding
cases, although their etiology of such diseases is different. In this section, the focus
will be on neurodegenerative diseases because of the following reasons: (i) they are
progressive, (ii) early diagnosis for these diseases are not available yet, (iii) they are
not effectively treatable, and (iv) they inflict enormous personal, societal, and
economic burdens. Some of them are aging relevant such as AD and PD; some of
them are not like ALS, Creutzfeldt-Jakob disease (mad cow disease), and other
human prion diseases (e.g., variant Creutzfeldt-Jakob diseases, Gerstmann-
Straussler-Scheinker syndrome, fatal familial insomnia, and kuru).
Specific polypeptides that go into aggregation are different in each amyloidosis;
however, there is a common feature in the behavior of these proteins; they all
present enriched β-sheet structure. Such proteins are normally soluble in cytosol
and in extracellular environment; however, somehow they progress into β-sheet-
enriched insoluble filamentous polymers [47]. Not all β-structure-enriched insolu-
ble filaments are an amyloid in nature. For example, some forms of SOD1-ALS are a
conformational disease which involves amorphous aggregation of misfolded SOD1
[16, 48]. That is to say, the common structural motif in all amyloid fibers consists of
cross-β-sheets. It is not uncommon that normally soluble proteins can undergo
β-sheet-enriched conformational rearrangement and they tend to be more insoluble
in nature. The concept of the β-sheet-enriched protein aggregation now becomes a
common trend for polypeptide chains regardless of amino acid sequence [27]. The
causes for the initiation of protein aggregation are not well documented; however,
oxidative stress-induced reactive oxygen species (ROS) may be involved due to the
role of ROS in several pathological disorders and aging [49, 50]. For example,
glycine (Gly) residues are particularly susceptible for loss of a hydrogen ion, which
results in the formation of Gly radical on the protein backbone which destabilizes
protein structure [51]. Consequently, buried hydrophobic regions of the protein are
exposed to the aqueous environment, and β-sheet structure formation is enhanced.
These newly formed β-sheet structures link with that of neighboring structure
which leads to the formation of a “seed” that eventually produces an aggregate [1].
2.2 Milestones for aggregate formation
Another characteristic in protein-folding disorders is a prolonged period in
aggregate/plaque formation before clinical manifestation becomes obvious [47]. In
aging-dependent neurodegenerative diseases such as AD and PD, aggregate/plaque
formation is a lengthy process, while in ALS, SOD1, and TDP-43, aggregates are
formed in the middle [52] or even younger ages [53]. One explanation for a lengthy
process would be that the initial nucleation of a misfolded protein is very small and
energetically stays in the upper level of the energy landscape (see Figure 3).
8
Therefore, the growth of the protein aggregate seed is kinetically unfavorable;
hence, recruitment of new aberrant proteins for aggregate formation takes a longer
period of time [54, 55]. Once the nucleation achieves a critical mass, the fibril
formation and subsequent plaque formation become accelerated. This is why clini-
cal manifestation of amyloidoses relevant to neurodegenerative disease mostly
appears in old age. This is mostly true for sporadic AD; however, in familial AD,
which represents only 5–10% of the total AD population, the disease onset tends to
occur at the middle age (50 and above). In Down syndrome, β-amyloid precursor
protein (APP), is encoded on chromosome 21 [47]. Patients with trisomy 21 develop
abundant Aβ aggregates in the brain at younger age. Therefore, the lifelong aggre-
gate formation is inevitable in Down syndrome patients, which supports the notion
that Down syndrome patients are at high risk in developing AD. In the USA, it is
estimated that more than a quarter million individuals live with Down syndrome
and all will develop AD pathology as early as in their 30s [56]. In summary, protein
aggregate formation starts at an early stage of life. This process is quicker in indi-
viduals with genetic conditions. Others display clinical signs at an old age as part of
aging process.
2.3 Regional protein aggregation
Cellular misfolded proteins are inclined to accumulate in nearby organs, in a
preferred cell type in a particular tissue [57], and in a particular cell organelle [58].
Although these proteins are distributed in systemic circulation, high concentrations
can be maintained in organs. For example, Aβ fragments deposition in brain regions
of AD patient, SOD1 and TDP-43 accumulation in spinal cord of ALS patients, and
α-synuclein plaques in brain regions (neocortex, hippocampus, substantia nigra,
thalamus, and cerebellum) of PD patients. Appearance of signature proteins (i.e.,
SOD1, TDP-43, α-synuclein, Aβ fragments, etc.) in systemic circulation supports
the development of a surrogate biomarker in the blood when tissue sampling is not
accessible [39].
It is interesting to note that misfolded aberrant proteins interact with apoptotic
proteins in organ-specific organelle. Pasinelli et al. have demonstrated that anti-
apoptotic protein Bcl-2 binds to detergent-insoluble mutant SOD1 (SOD1G93A) pro-
tein aggregates that are present in mitochondria from the spinal cord but not in the
liver in both mice and humans [58]. This observation suggests that misfolded
aberrant protein functions are location specific. Valentine has reviewed studies on
mutant SOD1 fragmentation in the Golgi apparatus, which may reveal early molec-
ular signals before the onset of ALS symptoms [59]. There are more emerging
studies in which emphasizing the region-specific protein aggregation can be con-
sidered a discriminatory signature in neurodegenerative diseases [60].
2.4 Systemic amyloidosis
The circulating proteins that have the potential to form extracellular amyloid
deposits in multiple organs have been recently reviewed [47]. Local production of
amyloid and non-amyloid protein species achieves the critical concentration for
oligomerization and fibrillogenesis in specific organs. For example, Aβ deposition
appears specifically in the brain tissue in AD. The Cu/Zn superoxide dismutase
(SOD1) and TDP-43 deposition are measurable in brain and spinal cord tissues in
ALS. These signature proteins can also be measurable in systemic circulation
(Table 1).
We have recently published a paper describing platelet TDP-43 measurements
as a proxy for brain tissue TDP-43 levels in AD patients [39]. This approach will aid
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to monitor the progress of aberrant protein aggregation in neurodegenerative
diseases.
In age-related neurodegenerative diseases, it is quite common to observe
β-sheet-enriched protein aggregates that are mostly detergent-insoluble. These
insoluble protein aggregates tend to accumulate inside the cell; however, ultra-
structure analysis of these aggregates may not be the same as that of extracellular
amyloid fibrils. The commonality of these aggregate-forming proteins was
discussed earlier (Section 1.3.1). Therefore, it is reasonably acceptable to classify the
aberrant protein aggregation-related neurodegenerative diseases as a special form of
amyloidosis [47].
Protein misfolding and subsequent aggregation are central in neurodegenerative
diseases; however, the protein behavior in forming aggregates is somehow disease
specific. In case of the α-synuclein, this protein is natively folded and normally
water soluble in the cell. In normal health conditions, α-synuclein participates in the
maintenance of synaptic vesicle supplies at the presynaptic terminals [61]. In PD,
this protein misfolds and accumulates in spherical filamentous structures called
Lewy bodies. This encapsulated structure forms particularly in dopaminergic and
noradrenergic brainstem neurons and causes premature cell death [62, 63]. There-
fore, Lewy bodies become a signature pattern for PD. Polyglutamine repeat of
corresponding proteins that are produced as the result of different mutant genes
becomes a distinct pattern in Huntington’s disease and several forms of familial
spinocerebellar ataxia [64]. AD is the only brain disorder that displays the accumu-
lation of amyloid forming proteins both extracellularly (Aβ fragments) and intra-
cellularly (hyper-phosphorylated tau) [47]. The question would be whether hyper-
phosphorylated tau neurofibrillary tangles or Aβ accumulation initiate AD. The
amyloid cascade hypothesis has been the most studied model of molecular patho-
genesis in AD. This is a long-debated issue in the scientific community which has
polarized into two schools of thought: “Baptists” that believe Aβ accumulation is the
starting event or “Tauist” that believes that tau-relevant neurofibrillary tangles are
the initiators for AD [65]. However, inherited mutations in tau protein do not
directly lead to AD; yet, it causes another devastating disorder, FTLD with PD [66].
It is now more probable that inherited mutations in APP or in one of the APP
cleaving proteases (e.g., presenilin/γ-secretase) cause aggressive early onset forms
of AD [67].
What are the initiation factors in sporadic AD which makes about 5–10% of all
AD cases? Not much is known so far. A new player in AD field is TDP-43 protein
which induces intramural Aβ accumulation via increasing β-secretase (BACE-1) [2].
As it can be seen in Figure 4, TDP-43 acts on an upstream in the APP structure and
may induce β-secretase. A ripple effect may induce to generate toxic Aβ fragments.
Table 1.
Extracellular fibril types in disease
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Levels of γ- and β-secretase activities are greater in brain tissue samples from AD
patients than non-demented control subjects [68, 69]. Experimental studies
conducted on 3xTg-AD (swAPP, PS1-M146V, tau-P301L) demonstrate that BACE-1
activity levels were elevated in the brain tissue and γ-secretase inhibitors reduced
the BACE-1 activity, suggesting that γ-secretase mediates oxidative stress-induced
expression of BACE-1 resulting in excessive Aβ production in AD [70]. Extracellular
cleavage of APP by BACE-1 creates a soluble extracellular fragment and a cell
membrane-bound fragment referred to as C99. Cleavage of C99 within its trans-
membrane domain by γ-secretase releases the intracellular domain of APP and pro-
duces Aβ. Since γ-secretase cleaves APP closer to the cell membrane than BACE1
does, it removes a fragment of the Aβ peptide. Initial cleavage of APP by α-secretase
rather than BACE-1 prevents eventual generation of Aβ [71]. It is clear that the most
notable neurodegenerative diseases (i.e., AD, ALS, FTLD, and PD) share a common
prominent pathological feature, TDP-43 proteinopathy. This issue has been recently
reviewed, and possibility of targeting TDP-43 as a common therapeutic approach to
formulate a treatment for neurodegenerative diseases was discussed [72]. In our
laboratory, we are also working on an assay methodology that uses peripheral
blood-derived platelet TDP-43 profile that may help for early diagnosis of such
diseases so that early treatment options could be available [39].
2.5 Aging and protein aggregation
Aging is the normal biological process that includes increased protein misfolding
and aggregation process due to either reduced levels of quality control checkpoints
such as chaperone system or proteasome complex. The proteins that form orderly
(amyloid fibers) and disorderly (amorphous aggregates and plaques) show some
common and essential biochemical and biophysical features that were discussed
earlier. Therefore, such age-related neurodegenerative diseases may be considered a
special form of amyloidoses [47]. The biochemical processes in aging are contribut-
ing to free radical-induced protein oxidation; hence, unnatural disulfide bridge
formations can contribute oxidized protein aggregation as well [73] . Dismutase
metalloenzyme (e.g., SOD1 and SOD2) activity levels are also reduced in aging
[74, 75]. This contributes the inefficient removal of reactive oxygen ions; hence,
more protein oxidation events take place, and subsequently protein aggregation
occurs. Principal unanswered questions about these neurodegenerative disorders
remain: how preciously native soluble proteins undergo partial unfolding, and does
aberrant refolding produce highly stable polypeptide polymers? We can still make
some predictions about the propensity of a given protein through PONDR® analy-
sis. This publicly available online prediction program (www.pondr.com) can be
utilized for predicting which regions of the protein will be more susceptible for
disorderliness which may increase the chance of aberrant protein refolding [76, 77].
It is clear that time and supraphysiological concentrations of predictable pro-
aggregate proteins are two important parameters in aggregation process. Other
factors such as oxidizable amino acids (e.g., cysteine and methionine), population,
local pH, and higher hydrophobic propensity of the protein help the oligomerization
process. Equilibrium between natively folded protein and aberrant-folded protein
can last for a long period of time. One approach would be that molten globule-like
intermediates have persistent structure in unstable α-structure. Stable β-structure of
the protein provides a template (seed) for the recruitment of additional peptide
chains through physical interaction of those two structural regions of the protein.
Finally, new hydrogen bonds form and stabilize the protein in an insoluble amyloid
fibril [78, 79]. On the other hand, fibril deposition is not a necessary feature in prion
disease. NMR structure of a domain of prion protein (PrR(121–231)) indicates that
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mutated amino acids in prion protein are involved in the maintenance of the
hydrophobic core [80]. Exactly, how prion conversion propagates? The disease is
currently under study [46]. As mentioned in Section 1.3, the ER contains a large
repertoire of molecular chaperones and folding catalysts [13, 14]. The ER protein-
folding system is also affected by aging process, and less fold-assisting proteins
would be available; hence, unfolded and misfolded protein levels would be expected
to be high. Two of the unconventional ER chaperone molecules are calnexin (Cnx)
and calreticulin (Crt) [81–83] as cited in [84]. In a pilot study, we demonstrated
that Cnx levels were reduced in aging rat brain as well as in neuronal cell culture
(Figure 7). This observation supports the other works published in literature stating
that protein-folding mechanisms are less efficient; therefore, aberrant-misfolded
proteins rise and form aggregates.
2.6 Misfolded aberrant proteins cause cell dysfunction
Dynamic equilibrium between misfolded and natively folded proteins may be
shifted in favor of protein misfolding and oligomerization in proteinopathy. No
definite amyloid fibrils are seen in diseases, suggesting that smaller diffusible toxic
protein species consisting of dimers, trimers, tetramers, and large oligomers may be
involved in cell cytotoxicity [47]. Therefore, forming a plaque or aggregate may be
considered a defense mechanism of cell against recruitment of more toxic protein
species. The aggregate in plaque no longer poses toxicity for cell life; however,
having such foreign structure in the cytosol or in extracellular milieu brings some
serious problems in cell homeostasis. For example, the plaques are insoluble and
indestructible by ubiquitinated proteasome system. The increased population of
such aggregates may overwhelm or even block the proteasome machinery. There-
fore, proteasome either slows down or becomes less functional. We have observed
such reduced proteasome activity in AD and ALS cases (Figure 5).
Another interference of such toxic protein species is that they nonspecifically
bind to receptors and channel proteins on the plasma membrane, thus interfering
with numerous cell-signaling events [16, 85]. Mitochondrion homeostasis should be
Figure 7.
Calnexin protein levels in aging. Calnexin protein levels were analyzed by Western blotting. Cnx levels were
reduced during the aging process in total brain homogenate, synaptic plasma membrane, and neuronal cell
culture. All samples were prepared from rat (n = 3) (unpublished data).
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taken into consideration as well. Many mitochondrial proteins are nuclear-coded
and transported into mitochondria [86]. These proteins are being transferred into
mitochondria via outer membrane pores. Although these pores are specific, such
small toxic protein species can nonspecifically bind the pores and slow down the
protein entries into mitochondria if not completely block. Consequently, energy
production mechanism of mitochondria may be compromised. Such hypothetical
ideas need to be experimentally tested and should provide more convincing data
about the cytotoxic effects of such protein species. Misfolded protein species get
involved in apoptosis induction. Pasinelli et al. have reported that anti-apoptotic
protein Bcl-2 interacts with both wt and mutant SOD1 (SOD1G93A) [58]. This
interaction induces apoptotic cascade because SOD1G93A mitochondria triggers
apoptosis more strongly than the cytosolic mutant SOD1 [87].
3. Therapeutic approach to protein-misfolding disease
Proper protein-folding in the cell occurs either in the cytoplasm or within the
secretory pathway. Dobson has reviewed this concept in detail [9].The readers are
referred to this review to attain more in-depth understanding of the protein-folding
relevant issues. The trend of misfolding protein increases when part of the poly-
peptide chain does not participate in a proper folding process. However, there are
mechanisms that are available for aiding protein-folding. Chaperones are the mole-
cules that collaborate with misfolded proteins to give a polypeptide chain several
opportunities to fold. ATP-dependent chaperone molecules are critical for ensuring
accuracy in proper folding [88]. The lumen of the ER also participates in protein-
folding process by modifying the secretory proteins while they are still associated
with the ER [89]. Any of these mechanistic failures contribute misfolded protein
accumulation. Despite the attempt to rescue misfolded proteins that are destined to
form insoluble aggregates, proteasomes, protein aggregate removal machinery,
degrade such proteins from the cell so that cell homeostasis be maintained.
Several other protein misfolding-relevant diseases are caused by conformational
modifications in extracellular milieu. Protein quality control-check systems of the
cell (chaperones and heat shock protein family) cannot be linked to such misfolded
protein population because such aggregation formation does not take place in cyto-
sol. However, recent studies demonstrate the presence of extracellular proteasome
machinery [92–94]. It is not clear yet whether these extracellular proteasomes are in
the same categories in that of cytosolic since a recent report demonstrated that such
extracellular proteasomes structurally differ from their cytosolic counterparts [94].
The major representatives of such disorders are the amyloidoses, in which
protein aggregation in the extracellular space is associated with the presence of
malfunctioned protein molecules [37, 90]. The chaperone-like small molecules may
have the potential to be included in the treatment options for amyloidoses [91]. The
more knowledge we attain on how chaperones and heat shock proteins interact with
protein-folding process the better design for small molecules would be feasible.
Folding process of proteins is an environment-dependent physicochemical
process. Some proteins have a folding issue where protein-folding takes place (i.e.,
lysosomal enzymes) while the others are efficiently folded in the ER but misfolded
and misassembled at the destination (i.e., amyloidogenic proteins). This knowledge
is helping industry-academia partnership for developing pharmacological interven-
tion that reduces the mutant protein production, increases the rate of clearance
of misfolded/mildly aggregated proteins, and increases the native stability of the
proteins.
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4. Conclusions
The majority of non-treatable neurodegenerative diseases are related to
misfolding protein-induced aggregation and insoluble plaque formation. This pro-
cess is very slow which makes early diagnosis of neurodegenerative diseases almost
impossible at this time. However, some predictive studies may help to identify the
proteins that have a tendency to form amyloid plaques. To know protein behavior
in various physiological conditions and environmental factors will contribute to
designing disease-specific drugs that interfere the aggregation formation in
neurodegenerative diseases.
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